```
=> d his

     (FILE 'HOME' ENTERED AT 13:16:07 ON 08 JUN 2004)

     FILE 'REGISTRY' ENTERED AT 13:16:50 ON 08 JUN 2004
L1             1 S NARATRIPTAN/CN

     FILE 'CAPLUS, USPATFULL' ENTERED AT 13:17:14 ON 08 JUN 2004
L2           168 FILE CAPLUS
L3            59 FILE USPATFULL
     TOTAL FOR ALL FILES
L4           227 S L1
L5           212 FILE CAPLUS
L6           250 FILE USPATFULL
     TOTAL FOR ALL FILES
L7           462 S NARATRIPTAN OR L1
L8           135 FILE CAPLUS
L9           188 FILE USPATFULL
     TOTAL FOR ALL FILES
L10          323 S L7 AND (MIGRAINE OR HEADACHE OR (HEAD ACHE))
L11           69 FILE CAPLUS
L12          188 FILE USPATFULL
     TOTAL FOR ALL FILES
L13          257 S (PROPHYL? OR PREVENT? OR INHIBIT? OR REDUC?) AND L10
L14            0 FILE CAPLUS
L15           24 FILE USPATFULL
     TOTAL FOR ALL FILES
L16           24 S L13 AND AURA

=> save all
ENTER NAME OR (END):l09575277a/l
L# LIST L1-L16 HAS BEEN SAVED AS 'L09575277A/L'
  75% OF LIMIT FOR SAVED L# LISTS REACHED

=>
```

L16 ANSWER 10 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2003:176426 USPATFULL
TITLE: Methods of treating **headaches** using 5-HT agonists in combination with long-acting NSAIDs
INVENTOR(S): Plachetka, John R., Chapel Hill, NC, United States
PATENT ASSIGNEE(S): Pozen Inc., Chapel Hill, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6586458	B1	20030701
APPLICATION INFO.:	US 2000-559753		20000427 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1998-151912, filed on 11 Sep 1998, now patented, Pat. No. US 6060499
Division of Ser. No. US 1997-907826, filed on 14 Aug 1997, now patented, Pat. No. US 5872145
Continuation-in-part of Ser. No. US 1999-253278, filed on 19 Feb 1999, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-24129P	19960816 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Jones, Dwayne C.
ASSISTANT EXAMINER: Delacroix-Muirheid, C.
LEGAL REPRESENTATIVE: Sanzo, Michael A., Fitch, Even, Tabin & Flannery
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 974
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 11 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2003:17999 USPATFULL
TITLE: Transdermal **migraine** therapy
INVENTOR(S): Aung-Din, Ronald, Sarasota, FL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003013753	A1	20030116
APPLICATION INFO.:	US 2002-163234	A1	20020605 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-296286P	20010605 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DAVIDSON, DAVIDSON & KAPPEL, LLC, 485 SEVENTH AVENUE, 14TH FLOOR, NEW YORK, NY, 10018
NUMBER OF CLAIMS: 46
EXEMPLARY CLAIM: 1
LINE COUNT: 1381
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 12 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2002:325709 USPATFULL
TITLE: Apparatus for administering composition for **inhibiting** cerebral neurovascular disorders and muscular **headaches**
INVENTOR(S): Levin, Bruce H., 241 S. 6th St., Philadelphia, PA, United States 19106

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6491940	B1	20021210
APPLICATION INFO.:	US 2000-492946		20000127 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-117398P	19990127 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Dees, Jose' G.
ASSISTANT EXAMINER: George, Konata M
LEGAL REPRESENTATIVE: Akin, Gump, Strauss, Hauer & Feld, L.L.P.
NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 4346
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 13 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2002:236079 USPATFULL
TITLE: Modulators of KCNQ potassium channels and use thereof in treating **migraine** and mechanistically related diseases
INVENTOR(S): Dworetzky, Steven I., Middlefield, CT, UNITED STATES
Gribkoff, Valentin K., Wallingford, CT, UNITED STATES
Kinney, Gene G., Collegeville, PA, UNITED STATES
Hewawasam, Piyasena, Middletown, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002128277	A1	20020912
APPLICATION INFO.:	US 2002-75703	A1	20020214 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-269967P	20010220 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Stephen B. Davis, BRISTOL-MYERS SQUIBB COMPANY, Patent Department, P. O. Box 4000, Princeton, NJ, 08543-4000
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 1482
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 14 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2002:186138 USPATFULL
TITLE: Combination therapy for the treatment of **migraine**
INVENTOR(S): Saper, Joel, Ann Arbor, MI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002099059	A1	20020725
APPLICATION INFO.:	US 2001-934276	A1	20010821 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-227350P	20000823 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT

DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
LINE COUNT: 416
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 15 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2002:88530 USPATFULL
TITLE: Pharmaceutical compositions containing tramadol for **migraine**
INVENTOR(S): Raber, Marc, Giessen, GERMANY, FEDERAL REPUBLIC OF
Momberger, Helmut, Marburg, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): ASTA Medica AG, Dresden, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6376550	B1	20020423
APPLICATION INFO.:	US 1999-247204		19990209 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Spivack, Phyllis G.
LEGAL REPRESENTATIVE: Goodwin Proctor LLP
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 568
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 16 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2002:17314 USPATFULL
TITLE: Compositions, kits, and methods for **inhibiting** cerebral neurovascular disorders and muscular **headaches**
INVENTOR(S): Levin, Bruce H., Merion, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002010194	A1	20020124
APPLICATION INFO.:	US 2001-775724	A1	20010201 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-118615, filed on 17 Jul 1998, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-72845P	19980128 (60)
	US 1998-84559P	19980506 (60)
	US 1997-90110P	19970721 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P., ONE COMMERCE SQUARE, 2005 MARKET STREET, SUITE 2200, PHILADELPHIA, PA, 19103
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 3431
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 17 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2001:237495 USPATFULL
TITLE: COMPOSITIONS, KITS, AND METHODS FOR **INHIBITING** CEREBRAL NEUROVASCULAR DISORDERS AND MUSCULAR

HEADACHES

INVENTOR(S): LEVIN, BRUCE H., PHILADELPHIA, PA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001055607	A1	20011227
	US 6432986	B2	20020813
APPLICATION INFO.:	US 1998-118615	A1	19980717 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-90110P	19970721 (60)
	US 1998-72845P	19980128 (60)
	US 1998-84559P	19980506 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P., ONE COMMERCE SQUARE, 2005 MARKET STREET, SUITE 2200, PHILADELPHIA, PA, 19103
NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 3832
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 18 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2001:205895 USPATFULL
TITLE: Methods and compositions for the regulation of vasoconstriction
INVENTOR(S): Waeber, Christian, Boston, MA, United States
Moskowitz, Michael A., Belmont, MA, United States
Yoshimura, Shin-Ichi, Zurich, Switzerland
Salomone, Salvatore, Somerville, MA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001041688	A1	20011115
APPLICATION INFO.:	US 2001-804987	A1	20010313 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-188859P	20000313 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Edward R. Gates, c/o Wolf, Greenfield & Sacks, P.C., Federal Reserve Plaza, 600 Atlantic Avenue, Boston, MA, 02210-2211
NUMBER OF CLAIMS: 85
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 2803
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 19 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2001:95472 USPATFULL
TITLE: Compositions, kits, apparatus, and methods for **inhibiting** cephalic inflammation
INVENTOR(S): Levin, Bruce H., Philadelphia, PA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001004644	A1	20010621
APPLICATION INFO.:	US 2000-737302	A1	20001215 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-118615, filed		

on 17 Jul 1998, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-170817P	19991215 (60)
	US 1997-90110P	19970721 (60)
	US 1998-72845P	19980128 (60)
	US 1998-84559P	19980506 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P., ONE COMMERCE SQUARE, 2005 MARKET STREET, SUITE 2200, PHILADELPHIA, PA, 19103
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 4241
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 20 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2001:29584 USPATFULL
TITLE: **Prevention** and treatment of **migraine**, cluster and other recurrent **headaches** using leukotriene antagonist drugs
INVENTOR(S): Sheftell, Fred D., 778 Long Ridge Rd., Stamford, CT, United States
Kevorkian, Robert C., West Granby, CT, United States
PATENT ASSIGNEE(S): Sheftell, Fred D., Stamford, CT, United States (U.S. individual)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6194432	B1	20010227	
APPLICATION INFO.:	US 1998-221015		19981223	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-103933P	19981013 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Krass, Frederick
LEGAL REPRESENTATIVE: Kelly, Patrick D.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 1001
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 21 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2000:64320 USPATFULL
TITLE: Preemptive **prophylaxis** of **migraine** device and method
INVENTOR(S): Cady, Roger K., 631 Riverview Rd., Ozark, MO, United States 65721
Farmer, Kathleen U., 225 Finley Dr., Ozark, MO, United States 65721

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6066092		20000523	
APPLICATION INFO.:	US 1998-185310		19981103	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-64879P	19971106 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: O'Connor, Cary
ASSISTANT EXAMINER: Natnithithadha, Navin
LEGAL REPRESENTATIVE: Husch & Eppenberger, LLC, Muir, Robert E.
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 313
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 22 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2000:57793 USPATFULL
TITLE: Anti-**migraine** methods and compositions using 5-HT agonists with long-acting NSAIDs
INVENTOR(S): Plachetka, John R., Chapel Hill, NC, United States
PATENT ASSIGNEE(S): Pozen, Inc., Chapel Hill, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6060499		20000509
APPLICATION INFO.:	US 1998-151912		19980911 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1997-907826, filed on 14 Aug 1997, now patented, Pat. No. US 5872145

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-24129P	19960816 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jones, Dwayne C.
ASSISTANT EXAMINER: Delacroix-Muirheid, C.
LEGAL REPRESENTATIVE: Sanzo, Michael A.Vinson & Elkins L.L.P.
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
LINE COUNT: 910
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 23 OF 24 USPATFULL on STN
ACCESSION NUMBER: 1999:22126 USPATFULL
TITLE: Formulation of 5-HT agonist and NSAID for treatment of **migraine**
INVENTOR(S): Plachetka, John R., Chapel Hill, NC, United States
PATENT ASSIGNEE(S): Pozen, Inc., Chapel Hill, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5872145		19990216
APPLICATION INFO.:	US 1997-907826		19970814 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-24129P	19960816 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jarvis, William R. A.
LEGAL REPRESENTATIVE: Lorusso & Loud
NUMBER OF CLAIMS: 61
EXEMPLARY CLAIM: 1
LINE COUNT: 915
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 24 OF 24 USPATFULL on STN

ACCESSION NUMBER:	1998:159979 USPATFULL			
TITLE:	Aromatic ethers derived from indoles which are useful as medicaments			
INVENTOR(S):	Perez, Michel, Castres, France Halazy, Serge, Lagarrigue, France John, Gareth, Les Salvages, France Valentin, Jean-Pierre, Catanet-Tolosan, France Pauwels, Peter, Lautrec, France			
PATENT ASSIGNEE(S):	Pierre Fabre Medicament, Boulogne, France (non-U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5852049		19981222	
	WO 9609288		19960328	
APPLICATION INFO.:	US 1997-809028		19970321	(8)
	WO 1995-FR1220		19950922	
			19970321	PCT 371 date
			19970321	PCT 102(e) date
	NUMBER		DATE	
PRIORITY INFORMATION:	FR 1994-11305		19940922	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Powers, Fiona T.			
LEGAL REPRESENTATIVE:	Rockey, Milnamow & Katz, Ltd.			
NUMBER OF CLAIMS:	28			
EXEMPLARY CLAIM:	1			
LINE COUNT:	1621			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>

		Relative E.sub.max *
12	6.16	0.8
13	6.51	1.2
16	6.62	1.36
19	7.8	1
Sumatriptan	5.75	1.26
Naratriptan	5.54	1

* review of the E.sub.max of the compounds mentioned to the E.sub.max of serotonin.

DETD . . . of the compounds of the present invention since, as the above examples show, they compare favorably with sumatriptan and with **naratriptan** as regards their binding to the human 5HT.sub.1D receptors and their efficacy as agonists in the rabbit saphenous vein contraction. . .

DETD . . . human therapy, the compounds of the general formula (I) according to the invention are particularly useful for the treatment and **prevention** of disorders linked to serotonin at the level of the central nervous system and of the vascular system. These compounds can therefore be used in the treatment and **prevention** of depression, obsessive compulsive disorders, panic attacks, bulimia, anorexia, aggressiveness, alcoholism, addiction to smoking, hypertension, nausea, sexual dysfunction, antisocial behavior, anxiety, **migraine**, vascular facial pain and chronic vascular cephalalgia, spasticity, Parkinson's or Alzheimer's disease and memory disorders.

ACCESSION NUMBER: 1998:159979 USPATFULL

TITLE: Aromatic ethers derived from indoles which are useful as medicaments

INVENTOR(S): Perez, Michel, Castres, France
Halazy, Serge, Lagarrigue, France
John, Gareth, Les Salvages, France
Valentin, Jean-Pierre, Catanet-Tolosan, France
Pauwels, Peter, Lautrec, France

PATENT ASSIGNEE(S): Pierre Fabre Medicament, Boulogne, France (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5852049		19981222	
	WO 9609288		19960328	
APPLICATION INFO.:	US 1997-809028		19970321	(8)
	WO 1995-FR1220		19950922	
			19970321	PCT 371 date
			19970321	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1994-11305	19940922

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Powers, Fiona T.
LEGAL REPRESENTATIVE: Rockey, Milnamow & Katz, Ltd.
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
LINE COUNT: 1621
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

raineur population that, while experiencing initial relief (or avoidance of **migraine** in the case of treated precursor symptoms) upon administration of a 5-HT agonist, experience return of **migraine** or **migraine** symptoms within the next about 1 to 24 hours. As noted above, this group comprises perhaps 40% of those subjects that experience returns of **migraine** or **migraine** symptoms, whom initially respond to 5-HT agonist therapy. Although it is presently unknown if this is a continuation of the original **headache**, a new **headache** either due to the ongoing underlying pathology or perhaps related to the administration of the therapeutic agents used initially to treat the **migraine** symptoms, these terms will be considered synonymous as used herein without inferring a mechanism or cause of the secondary **headaches** described above.

SUMM "Rebound moderated" as to sumatriptan shall mean that at least about 20% of that 40% will not experience recurrence of **migraine** within the 24 hours subsequent to "initial **migraine** relief" as defined below, which translates into an 8% overall improvement in the response of an entire group. As to ergots, rebound moderated shall mean a statistically significant improvement in return of **migraine** or **migraine** symptoms.

SUMM G. "Initial **migraine** relief" shall be understood to be the **reduction** or abolition of **migraine** symptoms from first onset of either a **migraine** attack or the precursor indicia of a **migraine headache** such as the **aura** and visual "scotoma" in about a 24 hour period.

SUMM . . . over the time periods specified above. It is preferred that the dosage form provides blood levels consistent with rapid initial **migraine** relief and a **reduced** incidence of relapse **headache**.

SUMM J. "Enhanced therapeutic effect" in the context of this invention shall mean that the initial relief of **migraine** symptoms will occur more quickly with a claimed combination of two agents compared to the same doses of each component. . .

SUMM . . . the experienced clinician is able to monitor and adjust dosages as to each subject relative to the severity of the **migraine** attack and the presence of side-effects, generally available information on maximum common daily dosages of NSAIDs is useful as a. . .

SUMM . . . NSAID one can achieve an enhanced therapeutic effect initially (within the first 6 hours) and a lower incidence of relapse **headaches** within the first 24 hours after initial dosing.

SUMM . . . effect is achievable with sub-MED doses of one or both of these therapeutic agents which provides the additional benefit of **reduced** incidence of side effects associated with either or both agents. For example, combining ergotamine tartrate 0.5 mg (a sub-MED, instead of the standard dose of 1-3 mg) with 125-550 mg naproxen sodium will, in some instances, provide **migraine** relief with a lower incidence of adverse events such as cardiovascular complications, nausea, or ergotism, and lower risk of such. . . dose) combined with a suitable dose of naproxen sodium, either orally or by another route. In this instance, a significant **reduction** in sumatriptan side effects such as, but not limited to, tingling, weakness, flushing, asthenia, chest and upper body pressure and. . .

SUMM . . . other 5-HT agents, including those of the ergot structure, are thought to exert their beneficial effect in migraineurs by either **reducing** the release of pro-inflammatory mediators around certain nerves and blood vessels or by vasoconstriction of selected blood vessels in the. . .

SUMM NSAIDs such as naproxen sodium are thought to relieve **migraine** pain through their known analgesic action, but may also relieve symptoms by **reducing** the neurogenic and vascular inflammation secondary to their known anti-inflammatory actions or by other mechanisms such as, but not limited to, platelet **inhibition** or **inhibition** of prostaglandin synthesis. In addition, naproxen and naproxen sodium

have half-lives on the order of 12-15 hours and produce a. . .

SUMM While not being bound by any particular theory, it is believed that the "relapse" **headache** often associated with 5-HT agonists is due to the original beneficial effect of the 5-HT agonists wearing off because of their short duration of action while a) the underlying trigger for the original **migraine** episode is still present and/or b) while the causative agent for the pain and other symptoms, presumably the vascular and/or. . .

SUMM In this context, the addition of a long-acting NSAID to a 5-HT agonist extends the period of effective anti-**migraine** action and **prevents** the relapse **headache** for occurring (or "rebound moderates"), whatever is its cause. In addition, because NSAIDs and 5-HT agonists, including those of both the 5-HT like structure and the ergot structure, have different pharmacologic properties and may relieve **migraine** through their own unique mechanisms, in some instances their combined use results in a greater beneficial therapeutic effect compared with. . .

SUMM . . . and diagnosing subjects that are subject to the vascular and/or neurogenic inflammation associated with subpopulations of migraineurs which experiences rebound **headaches** treatable by the present invention. As identified, this population is amenable to **migraine prophylaxis** tailored to such physiology, which a variety of therapies including, in some embodiments, maintenance levels of NSAID administration.

DETD An adult female migraineur complains of a **migraine** attack consisting of typical **migraine headache**, nausea and sensitivity to light and sound. She is dosed with a single oral tablet containing sumatriptan 25 mg and. . .

DETD An adult female migraineur is complaining of a **migraine** attack consisting of typical **migraine headache**, nausea and sensitivity to light and sound. She is dosed with a single subcutaneous injection of sumatriptan 6 mg and. . .

DETD An adult female migraineur is complaining of a **migraine** attack consisting of typical **migraine headache**, nausea and sensitivity to light and sound. She is dosed with a single oral tablet containing sumatriptan 12.5 mg and. . .

DETD An adult female migraineur, with a history of relapse **headache** in 6 to 24 hours when dosed with 6 mg sumatriptan alone, is complaining of a **migraine** attack consisting of typical **migraine headache**, nausea and sensitivity to light and sound. She is dosed with a single subcutaneous injection of sumatriptan 2 mg and. . .

DETD The 5-HT agonist and NSAID combined compositions of this invention possess valuable pharmacological properties. They effect long term **migraine** attack relief with substantially **reduced** incidence of relapse **migraine headache**. In some instances, they provide initial **migraine** relief with a **reduced** incidence of side effects, and/or greater efficacy. This effect can be demonstrated, for example, using the methods employed in the. . .

DETD . . . combination compositions (or separate use of both 5-HT agonist and NSAID) can be used in normal and in particularly recalcitrant **migraine** disease therapy.

CLM What is claimed is:

1. A method of treating **migraine** in a human comprising co-timely administering of a therapeutically effective amount of a 5-HT agonist coordinated with a therapeutically effective. . .

43. A method of treating **migraine** in a human comprising co-timely non-parenterally administering sumatriptan in an amount of about from about 1 mg to about 15. . .

ACCESSION NUMBER: 1999:22126 USPATFULL

TITLE: Formulation of 5-HT agonist and NSAID for treatment of **migraine**

INVENTOR(S): Plachetka, John R., Chapel Hill, NC, United States

PATENT ASSIGNEE(S):	Pozen, Inc., Chapel Hill, NC, United States (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5872145		19990216
APPLICATION INFO.:	US 1997-907826		19970814 (8)
	NUMBER		DATE
PRIORITY INFORMATION:	US 1996-24129P		19960816 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Jarvis, William R. A.		
LEGAL REPRESENTATIVE:	Lorusso & Loud		
NUMBER OF CLAIMS:	61		
EXEMPLARY CLAIM:	1		
LINE COUNT:	915		

and NSAID) can be used in normal and in particularly recalcitrant **migraine** disease therapy.

CLM What is claimed is:

1. In a method for treating a **migraine** patient by administering a 5-HT agonist, the improvement which comprises: concomitantly administering to said patient a long-acting, non-steroidal, anti-inflammatory drug (LA-NSAID) in an amount that, together with said 5-HT agonist, is effective to **reduce migraine** relapse or produce longer lasting efficacy compared to the administration of said 5-HT agonist in the absence of said LA-NSAID. . . .

2. In a method for treating a **migraine** patient by administering a long-acting, non-steroidal, anti-inflammatory drug (LA-NSAID), the improvement which comprises: concomitantly administering to said patient a 5-HT agonist in an amount that, together with said LA-NSAID, is effective to **reduce migraine** relapse or produce longer lasting efficacy compared to the administration of said LA-NSAID in the absence of said 5-HT agonist. . . .

3. A method for treating a **migraine** patient which comprises: (a) administering a 5-HT agonist to said patient and (b) administering a long-acting, non-steroidal, anti-inflammatory drug (LA-NSAID). . . administered and (ii) the respective amounts of said 5-HT agonist and said LA-NSAID administered to said patient are effective to **reduce migraine** relapse or produce longer lasting efficacy compared to the administration of said 5-HT agonist in the absence of said LA-NSAID. . .

4. A pharmaceutical composition in unit dose form, useful in treating a **migraine** patient, which comprises: (a) a 5-HT agonist and (b) a long-acting, non-steroidal, anti-inflammatory drug (LA-NSAID); wherein the respective amounts of. . . are effective, upon concomitant administration to said patient of one or more of said unit doses of said composition, to **reduce migraine** relapse or produce longer lasting efficacy compared to the administration of said 5-HT agonist in the absence of said LA-NSAID. . .

5. A therapeutic package for dispensing to, or for use in dispensing to, a **migraine** patient, which comprises: (a) one or more unit doses, each such unit dose comprising: (i) a 5-HT agonist and (ii). . . said unit dose are effective, upon concomitant administration to said patient of one or more of said unit doses, to **reduce migraine** relapse or produce longer lasting efficacy compared to the administration of said 5-HT agonist in the absence of said LA-NSAID. . . or unit doses, said container further containing or comprising labeling directing the use of said package in the treatment of **migraine**.

6. A method for **reducing** relapse in a **migraine** patient which comprises: (a) administering a 5-HT agonist to said patient and (b) administering a long-acting, non-steroidal, anti-inflammatory drug (LA-NSAID). . . administered and (ii) the respective amounts of said 5-HT agonist and said LA-NSAID administered to said patient are effective to **reduce migraine** relapse compared to the administration of said 5-HT agonist in the absence of said LA-NSAID or the administration of said. . .

7. A method for produce longer lasting efficacy in a **migraine** patient which comprises: (a) administering a 5-HT agonist to said patient and (b) administering a long-acting, non-steroidal, anti-inflammatory drug (LA-NSAID). . .

8. In a method for treating a **migraine** patient receiving 5-HT agonist monotherapy or long-acting, non-steroidal, anti-inflammatory drug (LA-NSAID) monotherapy, the improvement which comprises: concomitantly administering to said patient said LA-NSAID and said 5-HT agonist in respective amounts that working together **reduce migraine** relapse or produce longer lasting efficacy compared to

the administration of said monotherapy.

. . . or 8, wherein said 5-HT agonist is selected from the group consisting of sumatriptan, eletriptan, rizatriptan, frovatriptan, almotriptan, zolmitriptan, and **naratriptan**.

24. The improvement, method, or composition of claim 17, wherein said 5-HT agonist is **naratriptan**.

ACCESSION NUMBER:	2000:57793 USPATFULL		
TITLE:	Anti-**migraine** methods and compositions using 5-HT agonists with long-acting NSAIDs		
INVENTOR(S):	Plachetka, John R., Chapel Hill, NC, United States		
PATENT ASSIGNEE(S):	Pozen, Inc., Chapel Hill, NC, United States (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6060499		20000509
APPLICATION INFO.:	US 1998-151912		19980911 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-907826, filed on 14 Aug 1997, now patented, Pat. No. US 5872145		
	NUMBER		DATE
PRIORITY INFORMATION:	US 1996-24129P		19960816 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Jones, Dwayne C.		
ASSISTANT EXAMINER:	Delacroix-Muirheid, C.		
LEGAL REPRESENTATIVE:	Sanzo, Michael A.Vinson & Elkins L.L.P.		
NUMBER OF CLAIMS:	27		
EXEMPLARY CLAIM:	1		
LINE COUNT:	910		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

M What is claimed is:

1. A preemptive **prophylaxis migraine** method including the steps of: performing the cognitive tests of: a Simple Reaction Time, a Running Memory Continuous Performance Task,. . . the tests; and interpreting the results of the repeated tests as a percent of the baseline indicator of need for **prophylaxis**.

2. A preemptive **prophylaxis migraine** method as set forth in claim 1, wherein the step of establishing a baseline indicator uses a trial other than. . .

3. A preemptive **prophylaxis migraine** method as set forth in claim 2, wherein the trial used to establish the baseline indicator is the third trial.

. . .

4. A preemptive **prophylaxis migraine** method as set forth in claim 1, wherein the step of establishing a baseline indicator includes measuring the score in. . .

5. A preemptive **prophylaxis migraine** method as set forth in claim 4, wherein the step of establishing a baseline indicator includes converting the score in. . .

6. A preemptive **prophylaxis migraine** method as set forth in claim 5, wherein the step of repeating the tests includes converting the scores of the. . .

7. A preemptive **prophylaxis migraine** method as set forth in claim 6, including the step of administering an anti-**migraine** medication when the repeated test stanine differs from the baseline stanine.

8. A preemptive **prophylaxis migraine** method as set forth in claim 1, wherein the cognitive tests are performed in the order listed.

9. A preemptive **prophylaxis migraine** method as set forth in claim 1, wherein the listed cognitive tests are preceded by a Stanford Sleepiness Scale test.

. . .

10. A preemptive **prophylaxis migraine** method as set forth in claim 1, wherein the listed cognitive tests are preceded by a Mood Scale 2 test.

. . .

11. A preemptive **prophylaxis migraine** method as set forth in claim 1, wherein the listed cognitive tests are preceded by a Stanford Sleepiness Scale test. . . repeating the tests includes converting the scores of the repeated tests to stanine; and including the step of administering an anti-**migraine** medication when the repeated test stanine differs from the baseline stanine.

12. A preemptive **prophylaxis migraine** device including a microprocessor having a memory, a battery of tests loaded into the memory of the microprocessor and including. . .

13. A preemptive **prophylaxis migraine** device as set forth in claim 12, wherein the means for computing includes changing the scores to stanine.

14. A preemptive **prophylaxis migraine** device as set forth in claim 13, wherein the means for indicating a cognitive change is operative upon a drop. . .

15. A preemptive **prophylaxis migraine** device as set forth in claim 12, including a screen which is about 10 cm. square.

16. A preemptive **prophylaxis migraine** device as set forth in claim 12, including a screen and a key pad adjacent the screen.

17. A preemptive **prophylaxis migraine** device as set

forth in claim 16, including means for hinging the screen and key pad so that they may. . .

18. A preemptive **prophylaxis migraine** device as set forth in claim 16, wherein the key pad includes a plurality of mouse buttons.

19. A preemptive **prophylaxis migraine** device as set forth in claim 16, wherein the key pad includes a plurality of Mood Scale 2 buttons.

20. A preemptive **prophylaxis migraine** device as set forth in claim 16, wherein the key pad includes an on/off button, two mouse buttons, and three. . .

IT 103628-46-2, Sumatriptan **121679-13-8**, Naratriptan 139264-17-8, Zolmitriptan 143322-58-1, Eletriptan 144034-80-0, Rizatriptan 154323-57-6, Almotriptan 158747-02-5, Frovatriptan
(5-HT1 agonist and device for prophylaxis of migraine)

ACCESSION NUMBER: 2000:64320 USPATFULL

TITLE: Preemptive **prophylaxis** of **migraine** device and method

INVENTOR(S): Cady, Roger K., 631 Riverview Rd., Ozark, MO, United States 65721
Farmer, Kathleen U., 225 Finley Dr., Ozark, MO, United States 65721

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6066092		20000523
APPLICATION INFO.:	US 1998-185310		19981103 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-64879P	19971106 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: O'Connor, Cary
ASSISTANT EXAMINER: Natnithithadha, Navin
LEGAL REPRESENTATIVE: Husch & Eppenberger, LLC, Muir, Robert E.
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 313
CAS INDEXING IS AVAILABLE FOR THIS PATENT.